Take a look at our scientific poster, ‘VEGFR-3 signature expression by histology to classify patient population for the selective VEGFR-3 inhibitor EVT801’, recently presented by our experts at AACR 2023.
1 Evotec, Toulouse, France
2 Institut Universitaire du Cancer Toulouse-Oncopole, France
3 Department of Pathology, AP-HP Hôpital Saint Louis, Paris
4 Department of Dermatology, AP-HP Hôpital Saint Louis, Paris
5 Centre Léon Bérard, Lyon, France
6 Evotec, Abingdon, UK France
7 Kazia Therapeutics Ltd, Sydney, Australia; Toulouse France
